A Flow Cytometry-Based Cytotoxicity Assay for the Assessment of Human NK Cell Activity
Overview
Affiliations
Within the innate immune system, effector lymphocytes known as natural killer (NK) cells play an essential role in host defense against aberrant cells, specifically eliminating tumoral and virally infected cells. Approximately 30 known monogenic defects, together with a host of other pathological conditions, cause either functional or classic NK cell deficiency, manifesting in reduced or absent cytotoxic activity. Historically, cytotoxicity has been investigated with radioactive methods, which are cumbersome, expensive and potentially hazardous. This article describes a streamlined, clinically applicable flow cytometry-based method to quantify NK cell cytotoxic activity. In this assay, peripheral blood mononuclear cells (PBMCs) or purified NK cell preparations are co-incubated at different ratios with a target tumor cell line known to be sensitive to NK cell-mediated cytotoxicity (NKCC). The target cells are pre-labeled with a fluorescent dye to allow their discrimination from the effector cells (NK cells). After the incubation period, killed target cells are identified by a nucleic acid stain, which specifically permeates dead cells. This method is amenable to both diagnostic and research applications and, thanks to the multi-parameter capabilities of flow cytometry, has the added advantage of potentially enabling a deeper analysis of NK cell phenotype and function.
Erra L, Colado A, Brunello F, Prieto E, Goris V, Villa M Heliyon. 2025; 11(4):e42636.
PMID: 40066033 PMC: 11891720. DOI: 10.1016/j.heliyon.2025.e42636.
Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer.
Rogovskii V, Murugin V, Vorobyev N, Popov S, Sturov N, Krasheninnikov A Front Pharmacol. 2025; 15():1503317.
PMID: 39850551 PMC: 11754188. DOI: 10.3389/fphar.2024.1503317.
Hammoud M, Meena C, Dietze R, Hoffmann N, Szymanski W, Finkernagel F Cell Commun Signal. 2024; 22(1):555.
PMID: 39563446 PMC: 11575453. DOI: 10.1186/s12964-024-01940-z.
Al Balawi A, Alblwi N, Soliman R, El-Far A, Hassan M, El-Sewedy T BMC Pregnancy Childbirth. 2024; 24(1):709.
PMID: 39472874 PMC: 11523824. DOI: 10.1186/s12884-024-06914-0.
Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists.
Janez S, Guzelj S, Kocbek P, de Vlieger E, Slutter B, Jakopin Z J Med Chem. 2024; 67(19):17585-17607.
PMID: 39344184 PMC: 11472310. DOI: 10.1021/acs.jmedchem.4c01577.